Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NewAmsterdam Pharma Company ( (NAMS) ) has shared an update.
NewAmsterdam Pharma unveiled promising outcomes from its Phase 3 BROOKLYN trial, showcasing the potential of obicetrapib to significantly lower LDL-C and other cardiovascular risk markers in patients with heterozygous familial hypercholesterolemia. Achieving a notable 36.3% reduction in LDL-C compared to placebo, obicetrapib also demonstrated impressive results across secondary markers like Lp(a) and ApoB, while maintaining a safety profile akin to placebo. These results underscore obicetrapib’s potential to address unmet needs in lipid management and support its future as a pivotal cardiovascular treatment option.
Learn more about NAMS stock on TipRanks’ Stock Analysis page.
Trending Articles
- Boeing (NYSE:BA) Layoffs Expand, Start Hitting Multiple Factories
- Microsoft’s (NASDAQ:MSFT) New Computer is Exclusively a Cloud Machine
- Walmart (NYSE:WMT) Warns About Tariff-Driven Price Hikes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
